Field dossier · from the corpus

Sorafenib

0predicted collisions

Where this field is predicted to collide

No open collisions on this field in the current run.

Most cited work

Hepatocellular carcinoma

20216,635 citationsDOI ↗

Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC

2019449 citationsDOI ↗

Signals

2

Papers · in corpus

7.1k

Citations · corpus total

0.0%

Recent share · since 2024

2019–2021

Span · publication years

Who is doing the work

InsermFR1
University of California, San FranciscoUS1
Institució Catalana de Recerca i Estudis AvançatsES1
White Plains HospitalUS1
UCSF Helen Diller Family Comprehensive Cancer CenterUS1
Baptist Hospital of MiamiUS1
Université Paris CitéFR1
Hospital Clínic de BarcelonaES1

Most published researchers

Riccardo Lencioni1
Robin Kate Kelley1
Richard S. Finn1
Josep M. Llovet1
Augusto Villanueva1
Amit G. Singal1

Already lives beside

Fields this one already co-publishes with. A predicted collision is a departure from this neighbourhood, not an extension of it.

Hepatocellular carcinoma2 Cancer1 Cabozantinib1 Oncology1 Ramucirumab1 Internal medicine1 Gene knockdown1 CRISPR1 Cancer research1

Sorafenib · Raz0r Prism